Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms

The insulin-like growth factor (IGF)2/IGF1 receptor (IGF1R) signaling axis has an important role in intestinal carcinogenesis and overexpression of IGF2 is an accepted risk factor for colorectal cancer (CRC) development. Genetic amplifications and loss of imprinting contribute to the upregulation of IGF2, but insufficiently explain the extent of IGF2 expression in a subset of patients. Here, we show that IGF2 was specifically induced in the tumor stroma of CRC and identified cancer-associated fibroblasts (CAFs) as the major source. Further, we provide functional evidence that stromal IGF2, via the paracrine IGF1R/insulin receptor axis, activated pro-survival AKT signaling in CRC cell lines. In addition to its effects on malignant cells, autocrine IGF2/IGF1R signaling in CAFs induced myofibroblast differentiation in terms of alpha-smooth muscle actin expression and contractility in floating collagen gels. This was further augmented in concert with transforming growth factor-β (TGFβ) signaling suggesting a cooperative mechanism. However, we demonstrated that IGF2 neither induced TGFβ/smooth muscle actin/mothers against decapentaplegic (SMAD) signaling nor synergized with TGFβ to hyperactivate this pathway in two dimensional and three dimensional cultures. IGF2-mediated physical matrix remodeling by CAFs, but not changes in extracellular matrix-modifying proteases or other secreted factors acting in a paracrine manner on/in cancer cells, facilitated subsequent tumor cell invasion in organotypic co-cultures. Consistently, colon cancer cells co-inoculated with CAFs expressing endogenous IGF2 in mouse xenograft models exhibited elevated invasiveness and dissemination capacity, as well as increased local tumor regrowth after primary tumor resection compared with conditions with IGF2-deficient CAFs. In line, expression of IGF2 correlated with elevated relapse rates and poor survival in CRC patients. In agreement with our results, high-level coexpression of IGF2 and TGFβ was predicting adverse outcome with higher accuracy than increased expression of the individual genes alone. Taken together, we demonstrate that stroma-induced IGF2 promotes colon cancer progression in a paracrine and autocrine manner and propose IGF2 as potential target for tumor stroma cotargeting strategies.

[1]  Mikala Egeblad,et al.  Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling , 2009, Cell.

[2]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[3]  P. Jung,et al.  Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation. , 2012, Cancer cell.

[4]  S. Zaina,et al.  Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. , 2006, Cancer research.

[5]  M. Pollak,et al.  Insulin and insulin-like growth factor signalling in neoplasia , 2008, Nature Reviews Cancer.

[6]  A. Hoffman,et al.  Restoration of IGF2 imprinting by polycomb repressive complex 2 docking factor SUZ12 in colon cancer cells. , 2015, Experimental cell research.

[7]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[8]  Olivier De Wever,et al.  Stromal myofibroblasts are drivers of invasive cancer growth , 2008, International journal of cancer.

[9]  J. Riedemann,et al.  IGF1R signalling and its inhibition. , 2006, Endocrine-related cancer.

[10]  T. Speed,et al.  Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.

[11]  B. Hinz,et al.  Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. , 2001, Molecular biology of the cell.

[12]  P. Fu,et al.  IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. , 2013, Biochimica et biophysica acta.

[13]  A. Feinberg,et al.  Loss of Imprinting of Igf2 Alters Intestinal Maturation and Tumorigenesis in Mice , 2005, Science.

[14]  Mira Ayadi,et al.  Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value , 2013, PLoS medicine.

[15]  K. Kaibuchi,et al.  Direct interaction of insulin-like growth factor-1 receptor with leukemia-associated RhoGEF , 2001, The Journal of cell biology.

[16]  D. McMillan,et al.  The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[18]  T. Barrette,et al.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.

[19]  W. Sommergruber,et al.  IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction , 2014, Oncogene.

[20]  W. Bshara,et al.  Origin of the vasculature supporting growth of primary patient tumor xenografts , 2013, Journal of Translational Medicine.

[21]  W. Sommergruber,et al.  High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts , 2015, PloS one.

[22]  A. Desmoulière,et al.  The Myofibroblast: one function, multiple origins , 2010 .

[23]  J. Hauser,et al.  Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor. , 2008, Cancer research.

[24]  Shuji Ogino,et al.  Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. , 2010, Gastroenterology.

[25]  H. Nakano,et al.  β-Catenin and Smad3 regulate the activity and stability of myocardin-related transcription factor during epithelial–myofibroblast transition , 2011, Molecular biology of the cell.

[26]  R. Myers,et al.  Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data , 2005, Nucleic acids research.

[27]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[28]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[29]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[30]  Camille Stephan-Otto Attolini,et al.  Stromal gene expression defines poor-prognosis subtypes in colorectal cancer , 2015, Nature Genetics.

[31]  R. Baserga,et al.  IGF-I receptor signalling in transformation and differentiation , 2001, Molecular pathology : MP.

[32]  C. McCulloch,et al.  The compliance of collagen gels regulates transforming growth factor-β induction of α-smooth muscle actin in fibroblasts , 1999 .

[33]  G. Gabbiani,et al.  Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound healing. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[34]  B. Rikhof,et al.  Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. , 2007, Endocrine-related cancer.

[35]  C. Haslinger,et al.  Modeling colon adenocarcinomas in vitro a 3D co-culture system induces cancer-relevant pathways upon tumor cell and stromal fibroblast interaction. , 2011, The American journal of pathology.

[36]  S. Tartare-Deckert,et al.  LIF mediates proinvasive activation of stromal fibroblasts in cancer. , 2014, Cell reports.

[37]  Ker-Chau Li,et al.  Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling , 2014, Nature Communications.

[38]  G. Inghirami,et al.  Stromal contribution to the colorectal cancer transcriptome , 2015, Nature Genetics.

[39]  David B Jackson,et al.  EMT is the dominant program in human colon cancer , 2011, BMC Medical Genomics.

[40]  M. Heslin,et al.  Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma , 2011, British Journal of Cancer.

[41]  A. Harris,et al.  Igf2 ligand dependency of Pten+/− developmental and tumour phenotypes in the mouse , 2011, Oncogene.

[42]  C. McCulloch,et al.  Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. , 2004, The American journal of pathology.

[43]  S. Koujak,et al.  Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer , 2010, Molecular Cancer Therapeutics.

[44]  M. Tabrizi,et al.  Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. , 2011, Cancer research.

[45]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[46]  M. Pollak.  The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology , 2012, Clinical Cancer Research.

[47]  A. Desmoulière,et al.  Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts , 1993, The Journal of cell biology.

[48]  Marco Beccuti,et al.  The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets , 2015, Nature Communications.

[49]  Hitesh Shah.  How to calculate sample size in animal studies , 2011 .

[50]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[51]  A. Feinberg,et al.  Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. , 2005, Cancer research.

[52]  Ricardo Garcia,et al.  Biomechanical Remodeling of the Microenvironment by Stromal Caveolin-1 Favors Tumor Invasion and Metastasis , 2011, Cell.

[53]  P. Pauwels,et al.  Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling , 2012, Gut.

[54]  Joon-Oh Park,et al.  Activated cMET and IGF1R-Driven PI3K Signaling Predicts Poor Survival in Colorectal Cancers Independent of KRAS Mutational Status , 2014, PloS one.

[55]  C. Klein,et al.  Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.

[56]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[57]  G. Adolf,et al.  Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin , 2013, Molecular Cancer Therapeutics.

[58]  P. Hein,et al.  Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium , 2000, Breast Cancer Research.

[59]  X. Lu,et al.  Differential activation of IGF-II promoters P3 and P4 in Caco-2 cells during growth and differentiation. , 1998, Gastroenterology.

[60]  M. Pollak,et al.  The Type 1 Insulin-Like Growth Factor Receptor Pathway , 2008, Clinical Cancer Research.

[61]  C. McCulloch,et al.  Integrity of cell-cell contacts is a critical regulator of TGF-beta 1-induced epithelial-to-myofibroblast transition: role for beta-catenin. , 2004, The American journal of pathology.

[62]  S. Rennard,et al.  Smad3 mediates TGF-beta1-induced collagen gel contraction by human lung fibroblasts. , 2006, Biochemical and biophysical research communications.

[63]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[64]  D. Moretta,et al.  Precursor Igf-ii (Proigf-ii) And Mature Igf-ii (Migf-ii) Induce Bcl-2 And Bcl-xl Expression Through Different Signaling Pathways In Breast Cancer Cells , 2008, Growth factors.

[65]  Terence P. Speed,et al.  A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..

[66]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  S. Zaina,et al.  Soluble IGF 2 Receptor Rescues ApcMin / + Intestinal Adenoma Progression Induced by Igf 2 Loss of Imprinting , 2006 .

[68]  E. Bruyneel,et al.  Tenascin‐C and SF/HGF produced by myofibroblasts in vitro provide convergent proinvasive signals to human colon cancer cells through RhoA and Rac , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  N. Hay,et al.  The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. , 1997, Genes & development.

[70]  C. Livingstone.  IGF2 and cancer. , 2013, Endocrine-related cancer.

[71]  Raghu Kalluri,et al.  Fibroblasts in cancer , 2006, Nature Reviews Cancer.

[72]  A. Feinberg,et al.  Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk , 2003, Science.

[73]  M. Monden,et al.  Stromal Myofibroblasts Predict Disease Recurrence for Colorectal Cancer , 2007, Clinical Cancer Research.

[74]  M. Pollak.  The insulin and insulin-like growth factor receptor family in neoplasia: an update , 2012, Nature Reviews Cancer.

[75]  C. McCulloch,et al.  The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. , 1999, The American journal of pathology.

[76]  E. Small.  The Actin–MRTF–SRF Gene Regulatory Axis and Myofibroblast Differentiation , 2012, Journal of Cardiovascular Translational Research.

[77]  Gloria S. Huang,et al.  Insulin-Like Growth Factor 2 Silencing Restores Taxol Sensitivity in Drug Resistant Ovarian Cancer , 2014, PloS one.

[78]  R. Baxter,et al.  Biochemical Characterization of Individual Human Glycosylated pro-Insulin-like Growth Factor (IGF)-II and big-IGF-II Isoforms Associated with Cancer , 2012, The Journal of Biological Chemistry.

[79]  Takeshi Imamura,et al.  The ALK‐5 inhibitor A‐83‐01 inhibits Smad signaling and epithelial‐to‐mesenchymal transition by transforming growth factor‐β , 2005, Cancer science.

[80]  E. Sahai,et al.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells , 2007, Nature Cell Biology.

[81]  T. Ørntoft,et al.  Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer , 2009, Clinical Cancer Research.

[82]  Sabine Tejpar,et al.  IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies , 2015, Science Translational Medicine.

[83]  Kenichi Sugihara,et al.  Microarray Analysis of Colorectal Cancer Stromal Tissue Reveals Upregulation of Two Oncogenic miRNA Clusters , 2012, Clinical Cancer Research.

[84]  K. Takano,et al.  Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia. , 2006, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[85]  M. Rubini,et al.  Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[86]  W. Hahn,et al.  Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.

[87]  M. Hengstschläger,et al.  Efficient siRNA-mediated prolonged gene silencing in human amniotic fluid stem cells , 2010, Nature Protocols.